Summit Therapeutics Inc.

SMMT

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Baker Bros. Advisors Rock Springs Capital

AI Signal

**Signal Note: Baker Bros.

AI analyst context — unlock full analysis

Catalysts

PDUFANov 14, 2026ivonescimabNSCLC

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 36,391,063Value: $636.5M

**Signal Note: Baker Bros. Initiates Major Position in Summit Therapeutics (SMMT)** Baker Bros. Advisors, the largest biotech-specialist fund known for extremely concentrated, high-conviction bets, initiated a new position of ~36.4M shares in Summit Therapeutics, representing a substantial capital deployment ahead of the Nov. 14, 2026 PDUFA date for ivonescimab, a bispecific PD-1/VEGF antibody in non-small cell lung cancer (NSCLC). The size and timing of this initiation suggest strong conviction in the ivonescimab regulatory pathway, likely informed by clinical data readouts positioning the drug as a potential best-in-class competitor to established PD-(L)1 and anti-angiogenic combination regimens. This is a high-signal move given Baker Bros.' track record of deep diligence in onc

Rock Springs CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS2 funds ARGX2 funds RCUS2 funds CLDX2 funds NGNE2 funds CNTA2 funds DYN2 funds ELVN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Rock Springs Healthcare Initiates SMMT Position** Rock Springs Capital's $12.4M entry into Summit Therapeutics signals conviction in ivonescimab's NSCLC approval pathway, with a PDUFA decision expected November 2024. The PD-L1/VEGF bispecific represents a competitive play in the crowded first-line NSCLC space, where efficacy versus established combos (e.g., Keytruda + chemo) and durability of response remain key valuation drivers. Near-term catalyst clarity on regulatory outcome and label positioning will likely drive volatility.